Paul G. Richardson

Paul G. Richardson, MD is Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and holds the RJ Corman Professorship of Medicine at Harvard Medical School. He is one of the world's foremost clinical trialists in multiple myeloma, best known for leading the APEX trial — the landmark phase III study that established bortezomib's superiority over high-dose dexamethasone in relapsed/refractory myeloma and resulted in full FDA approval of bortezomib in 2005. Dr. Richardson subsequently spearheaded the clinical development of pomalidomide, leading phase I/II studies that defined its activity in double-refractory myeloma and the phase IIIb STRATUS trial that supported its FDA approval in 2013. He has served as principal investigator on dozens of pivotal myeloma trials spanning proteasome inhibitors, IMiDs, histone deacetylase inhibitors, and novel antibody-drug conjugates. A particular focus of his work has been defining optimal combination regimens and sequencing strategies for relapsed/refractory myeloma, including the VRd (bortezomib, lenalidomide, dexamethasone) backbone and carfilzomib-based triplets. Dr. Richardson has published more than 700 peer-reviewed manuscripts and lectures extensively at ASH, ASCO, and EHA congresses.